Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001966 · ClinicalTrials.gov registry record · Phase 2

Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome

A Phase 2 study, sponsored by National Human Genome Research Institute (NHGRI).

Completed
Registry status
Phase 2
Development phase
40
Enrollment target

NCT00001966 is a Phase 2 study that has completed, run by National Human Genome Research Institute (NHGRI). The registered enrollment target is 40 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001966, a Phase 2 study, has completed, sponsored by National Human Genome Research Institute (NHGRI).

COMPLETED
Registry status
Phase 2
Development phase
40 participants
Enrollment target

Study Summary

This study will assess the effectiveness of mind-body therapy in relieving pain in patients with Ehlers-Danlos syndrome. This syndrome is a hereditary condition caused by a connective tissue defect and is often associated with chronic pain poorly controlled by medication or physical therapy. Mind-body therapy comprises various complementary or alternative medicine techniques such as meditation, guided imagery, stress management, and group psychotherapy. Adult patients with Ehlers-Danlos syndrome who have chronic pain may be eligible for this 4 1/2 \[Note: if the symbol is unreadable, it is four and one-half\] to 5-month study. Patients not already enrolled in NHGRI's protocol 97-HG-0089 will undergo a history, physical examination, and brief interview before being accepted. Participants will attend 2-hour group sessions of mind-body therapy at NIH each week for at least 10 weeks. They will receive training in meditation, yoga breathing, guided imagery, and stress management in these sessions and will be asked to also practice the treatments at home each day. Patients may continue their regular medications and pain treatment with their private physicians during the course of the study. Participants will fill out a packet of questionnaires about their pain, health, and quality of life at three intervals: when they enroll in the study, at the end of treatment, and 12 weeks after treatment ends. At these same time intervals, patients will come to NIH for a test of their physical ability to walk and climb stairs. Patients will keep a diary and pain symptoms and medications for 1 week before treatment begins and 1 week after it ends, and will fill out questionnaires about pain during the entire study period.

Interventions

  • DRUG Mind-body therapy

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2000-01
Est. Completion 2001-01
Phase Phase 2

What the Registry Record Tells You About NCT00001966

The ClinicalTrials.gov registry entry for NCT00001966 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Human Genome Research Institute (NHGRI), which has 185 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Mind-body therapy is the first listed.

NCT00001966 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00001966 about?

NCT00001966 is a clinical study titled "Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome". This study will assess the effectiveness of mind-body therapy in relieving pain in patients with Ehlers-Danlos syndrome. This syndrome is a hereditary condition caused by a connective tissue defect and is often associated with chronic pain poorly controlled by medication or physical therapy. Mind-bo...

What is the current status of trial NCT00001966?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2000-01. Estimated completion is 2001-01.

What interventions are being tested in trial NCT00001966?

The interventions under investigation include: Mind-body therapy (DRUG).

Who is sponsoring clinical trial NCT00001966?

This trial is sponsored by National Human Genome Research Institute (NHGRI), which has 185 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.